True. And c'mon you guys really think InMed would bring in an Eli Lily biosynthesis guy, have all these top tier people on their team, look at other biosynthesis processes out there, apply for a patent, and still overlook one company's method of biosynthesis that took an average investor minutes to google?
I'm sure these guys know what they're doing. And as for the CEO selling shares I think it's possible he saw the whole sector going down after the Jeff Sessions crackdown on weed in the states and saw it as an opportunity to sell and buy back at a lower price. Good move if you ask me cause now he can buy back in the $1 range. Not to mention I've read that he has 4 million options.
I'm staying long on this.
News 
Market Data 
Discover 
